Bicara Therapeutics Inc. (BCAX) announced on Monday the outcomes of its Phase 1/1b dose expansion cohort, which examined the efficacy of combining ficerafusp alfa with pembrolizumab in patients with squamous cell carcinoma of the anal canal (SCAC) who were receiving second-line or later treatment.
Involving 28 participants, the study demonstrated a confirmed overall response rate of 25%, featuring six partial responses and one complete response.
The company also reported a median progression-free survival (PFS) of 2.9 months, with a one-year PFS rate of 40.7%.
Bicara emphasized the significance of the initial data, suggesting ficerafusp alfa's vital role in SCAC treatment possibilities.
As of now, Bicara’s shares are trading at $12.00 on the Nasdaq, marking a 3.40% increase.
